Skip to content

Assessment of Nasal Blockage Using Oscillometry in Patients with Allergic Rhinitis Before and After Treatment

Evaluation of Nasal Resistance using Oscillometry in patients with Allergic Rhinitis: A Prospective Interventional Study - NORA Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/06/111642
Enrollment
150
Registered
2026-06-01
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R098- Other specified symptoms and signsinvolving the circulatory and respiratory systems

Interventions

Intervention1: Nasal Oscillometry with House Dust Mite (HDM) Nasal Provocation Testing in Patients with Allergic Rhinitis: Participants will undergo baseline nasal oscillometry using the Tremoflo C-1

Sponsors

Sir Ganga Ram Hoapital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Participants aged 12 years and above of either sex will be eligible for enrollment. The Allergic Rhinitis (AR) group will include adolescents and adults with a clinical diagnosis of allergic rhinitis characterized by typical symptoms such as sneezing, rhinorrhea, nasal obstruction, and or nasal itching, with a Visual Analogue Scale (VAS) score greather than or equal to 30 and documented sensitization to house dust mite (HDM) demonstrated by either a positive skin prick test (wheal diameter greater than or equal to 3 mm above negative control) or serum specific IgE positivity. The healthy control group will comprise age- and sex-matched individuals without a history of allergic rhinitis, asthma, or other atopic diseases and with negative HDM sensitization testing.

Exclusion criteria

Exclusion criteria: Participants will be excluded if they have uncontrolled asthma; active upper or lower respiratory tract infection; structural abnormalities of the nose, nasopharynx, or upper airway; history of tracheal stenosis, laryngeal disorders, tracheal surgery, recent nasal trauma, or nasal surgery; previous episodes of angioedema or choking; known anaphylaxis to house dust mite; pregnancy or lactation; recent systemic corticosteroid use (more than 10 mg/day within the preceding 2 weeks); vaccination within the previous 7 days or planned within 24 hours after testing; or inability/unwillingness to comply with study procedures and follow-up requirements.

Design outcomes

Primary

MeasureTime frame
Nasal airway resistance (oscillometric resistance values at predefined frequencies).Timepoint: Baseline assessment at enrollment before intervention (nasal provocation test), expected within a single study visit.

Secondary

MeasureTime frame
Change in nasal airway resistance following House Dust Mite (HDM) nasal provocation test as measured by oscillometry and correlation with VAS and TNSS scores.Timepoint: 10 minutes after HDM nasal provocation test.

Countries

India

Contacts

Public ContactNeeraj Gupta

Sir Ganga Ram Hospital

drneeraj1979@gmail.com9871070375

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026